Paasa Logo
Molecular Partners AG logo
MOLNNASDAQMarket closedOpens 9:30am ET

Molecular Partners AG

$3.90Last updated
+$0.04 (1.04%)Past day
Timezone

Molecular Partners AG (NASDAQ: MOLN) is trading at $3.90, about ₹375 at today's USD/INR rate, as of 29 Sep 2026, 4:00 PM ET, up 1.04% today. Indian residents can buy Molecular Partners from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:$3.88
Previous close:$3.86
Volume:654.00

Today's low

$3.75

Today's high

$3.90

52 week low

$3.53

52 week high

$5.36

MOLN opened at $3.88, closed previously at $3.86, and has traded between $3.53 and $5.36 over the past 52 weeks.

About

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Country
CH
CEO
Patrick Amstutz
Exchange listed on
NASDAQ
Industry
Biotechnology
Base currency
USD
Full Time Employees
134
Sector
Healthcare
IPO date
16/06/2021

Key statistics

Avg. volume

4.38K

Market cap

$146.29M

P/E Ratio

-2.42

Price-to-sales ratio

0.00

Enterprise value

CHF 49.88M

Free cash flow yield

-40.32%

Debt-to-equity ratio

0.05

Return on equity

-76.74%

ROIC

-62.98%

Beta

0.69

Dividend yield

0.00%

Last dividend

$0.00

Financial overview

Revenue

CHF 0.00

Earnings per share

-CHF 1.65

Free cash flow

-CHF 51.97M

Net profit margin

0.00%

Gross margin

0.00%

EBITDA

-CHF 59.49M

Revenue growth

-100.00%

Similar securities

This is not an investment recommendation

How to buy Molecular Partners from India

Indian residents can buy Molecular Partners shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.

  3. Search for Molecular Partners and place an order

    Find Molecular Partners by name or by its ticker, MOLN, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Molecular Partners trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Molecular Partners position in USD and INR. Molecular Partners pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Molecular Partners from India

Trading and taxes when buying Molecular Partners from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneMolecular Partners does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained

Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

FAQs

Can Indian residents buy Molecular Partners stock?

Yes. Molecular Partners (MOLN) has been listed on NASDAQ since 2021, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

How much does one Molecular Partners share cost in rupees?

One Molecular Partners share is $3.90 — about ₹375 at a USD/INR rate of 96.06 on 29 Sep 2026. Both the Molecular Partners price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Molecular Partners from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

Can I buy whole shares of Molecular Partners?

Yes. One Molecular Partners share is $3.90, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Molecular Partners.

How are gains on Molecular Partners shares taxed in India?

The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Molecular Partners price. Paasa issues a capital-gains statement for your return.

Does Molecular Partners pay a dividend?

No. Molecular Partners does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Molecular Partners from India?

NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.

Is Molecular Partners a United States company, and does that change how it is taxed?

Molecular Partners trades on NASDAQ in US dollars, but the company is domiciled in Switzerland. Molecular Partners trades as an American Depositary Receipt rather than an ordinary share. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Your India-side capital-gains treatment is the same either way.

Do I have to declare Molecular Partners shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Molecular Partners holding, its cost and its closing value.

How do I sell Molecular Partners and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.